Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Sanofi (CIK 1121404) reported $336.0M across 7 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: MGTX ($105.6M, 31.44%), INBX ($77.8M, 23.17%), NVAX ($56.0M, 16.67%), ANAB ($30.4M, 9.04%), ($29.2M, 8.69%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | $105.6M | 31.44% | 12.2M | Hold |
| 2 | INBX | Inhibrx Biosciences, Inc. | $77.8M | 23.17% | 1.2M | Hold |
| 3 | NVAX | Novavax | $56.0M | 16.67% | 6.9M | Hold |
| 4 | ANAB | AnaptysBio | $30.4M | 9.04% | 821,917 | Hold |
| 5 | Agomab Therapeutics NV | $29.2M | 8.69% | 2.8M | New | |
| 6 | MapLight Therapeutics Inc. | $18.5M | 5.52% | 912,041 | Hold | |
| 7 | IMRX | Immuneering Corp | $14.3M | 4.25% | 2.7M | Hold |
| 8 | ELDN | Eledon | $2.5M | 0.75% | 814,980 | Hold |
| 9 | QTTB | Q32 Bio Inc. | $1.6M | 0.47% | 244,083 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31